John J. Brems

John J. Brems

Auto-generated profile, based on publicly available information

John J. Brems

Department of Surgery, Loyola University, 2160 S First Ave, Bldg 110, Rm 3268, Maywood, IL 60153, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
RTRyan M. Thomas
Ryan M. Thomas
JBJohn J. Brems
John J. Brems
GGGrace Guzman-Hartman
Grace Guzman-Hartman
SYSherri Yong
Sherri Yong
PCPatricia Cavaliere
Patricia Cavaliere
DTDavid H. Van Thiel
David H. Van Thiel
An analysis of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplant Registry data shows that the greater the viral load at the time of transplantation, the more rapidly clinically evident posttransplantation hepatitis C virus (HCV) disease recurs. These data suggest that aggressive pretransplantation treatment of HCV might delay recurrent posttransplantation HCV disease and enhance posttransplantation survival. We have taken an aggressive approach to treating HCV infection pretransplantation with the use of high-dose (5 MU) daily interferon α2b in an effort to clear the virus before transplantation. A total of 27 patients with HCV-induced cirrhosis were seen and underwent transplantation at Loyola University Medical Center (Maywood, IL) between February 1997 and December 2001. There were 22 men and five women, with a mean age of 56 ± 2 years. The majority had genotype 1 disease (67%). Of the 27 patients, 7 had a baseline platelet count <50,000/mm3 and were excluded from interferon therapy. The remaining 20 were treated for a mean of 14 ± 2.5 (range, 0.5 to 33.5) months before orthotopic liver transplantation (OLT). Twelve (60%) responded to the therapy with serologic clearance of HCV before OLT. The mean time from initiation of therapy to the first negative qualitative polymerase chain reaction was 4.5 ± 1.5 (range, 0.5 to 12) months. Four of the 12 patients in whom the virus cleared did not have evidence of HCV recurrence after OLT, representing 20% of those treated and 33% of those who had HCV clearance before OLT. The duration of post-OLT freedom from HCV infection in these individuals has been 33.6 ± 11.3 (range, 0 to 47.4) months. These data suggest that with careful supervision, cirrhotic patients can tolerate high-dose interferon. In addition, a viral clearance can be achieved in a significant number of cirrhotic patients with high-dose interferon. One third of patients, in whom the HCV cleared before OLT, did not have evidence of disease recurrence after OLT. It is thus anticipated that with early and aggressive pre-OLT HCV therapy, possibly with the use of pegylated interferon, even better results may be obtained.

1 May 2002 in Archives of Surgery
Verified
Journal Article
Open access
PDF file
DHDavid Holt
David Holt
RTRyan M. Thomas
Ryan M. Thomas
DTDavid Van Thiel
David Van Thiel
JBJohn J. Brems
John J. Brems
THE INITIAL orthotopic liver transplantation (OLT) experience for patients with hepatitis B virus (HBV)-induced liver failure was dismal.1,2 These patients often developed recurrent HBV infection after transplantation, resulting in subsequent liver failure and death. Therefore, HBV infection became a contraindication for liver transplantation. This poor initial experience subsequently improved with the use of immunoprophylaxis, namely, hepatitis B immune globulin (HBIG). This therapy resulted in outcomes for this population comparable to those of patients who underwent transplantation for non-HBV disease. Another drug, lamivudine, has also been shown to be effective in eradicating HBV viremia and has been used as additional prophylaxis for HBV-infected patients undergoing OLT.

1 December 2002 in The American Journal of Surgery
Verified
Journal Article
Closed access
PDF file
RRRishindra M Reddy
Rishindra M Reddy
ARAdam Riker
Adam Riker
DMDeborah Marra
Deborah Marra
RTRyan M. Thomas
Ryan M. Thomas
JBJohn J Brems
John J Brems